ArticleProstate international2026
AR-V7 expression in primary non-metastatic prostate cancer and its role in disease progression following initial therapy: a systematic review and meta-analysis.
Article in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the Androgen Receptor and Associated Cofactors in Prostate Cancer: Novel Approaches and Future Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic role of androgen receptor variant 7 (AR-V7) in non-metastatic prostate cancer remains unclear. We conducted a systematic review and meta-analysis to evaluate its impact on primary treatment outcomes and disease progression. Methods: We systematically searched PubMed, Embase, and Cochrane Central for observational studies and randomized controlled trials (RCTs) comparing AR-V7-positive and AR-V7-negative patients with non-metastatic prostate cancer. The primary outcomes were overall survival (OS) and biochemical recurrenc (BCR). Secondary outcomes, including progression-free survival (PFS), cancer-specific survival (CSS), and the incidence of castration-resistant prostate cancer (CRPC), were assessed as non-meta-analyzable endpoints. Hazard ratios (HRs) and risk ratios (RRs) with 95 % confidence intervals (CIs) were calculated using a random effects model. Statistical analyses were conducted in Review Manager software (version). Results: Seven studies were included, comprising 1,383 patients. AR-V7 expression was associated with significantly worse OS (HR 5.75; 95 % CI 2.24-14.78; Conclusion: AR-V7 expression is a negative prognostic marker in non-metastatic prostate cancer, associated with significantly reduced OS and increased CRPC progression. While no significant difference was observed in BCR, the trend suggests potential implications for disease monitoring. Further studies with standardized detection methods are needed to clarify AR-V7's role in risk stratification and treatment decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.